The safety of warfarin therapy in the nursing home setting

被引:65
作者
Gurwitz, Jerry H.
Field, Terry S.
Radford, Martha J.
Harrold, Leslie R.
Becker, Richard
Reed, George
DeBellis, Kristin
Moldoff, Jason
Verzier, Nancy
机构
[1] Univ Massachusetts, Meyers Primary Care Inst, Sch Med, Fallon Clin Fdn, Worcester, MA 01605 USA
[2] Fallon Community Hlth Plan, Worcester, MA USA
[3] Univ Massachusetts, Sch Med, Div Geriatr Med, Worcester, MA 01605 USA
[4] CUNY, Sch Med, New York, NY 10021 USA
[5] Duke Univ, Sch Med, Div Hematol, Durham, NC USA
[6] Duke Univ, Sch Med, Div Cardiol, Durham, NC USA
[7] Qualidigm Inc, Middletown, CT USA
关键词
long-term care; medication safety; nursing homes; oral anticoagulants; warfarin;
D O I
10.1016/j.amjmed.2006.07.045
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: We examined the preventability of adverse warfarin-related events and potential adverse warfarin-related events ("near misses") in the nursing home setting. METHODS: We performed a cohort study of all long-term care residents of 25 nursing homes (bed size range, 90-360) in Connecticut during a 12-month observation period. The total number of residents in these facilities ranged from 2946 to 3212 per quarter. There were 490 residents who received warfarin therapy. Possible warfarin-related incidents were detected by quarterly retrospective review of nursing home records by trained nurse abstractors. Each incident was independently classified by 2 physician-reviewers to determine whether it constituted a warfarin-related event, its severity, and its preventability. The primary outcome was an adverse warfarin-related event, defined as an injury associated with the use of warfarin. Potential adverse warfarin-related events were defined as situations in which the international normalized ratio (INR) was noted to be 4.5 or greater, an error in management was noted, but no injury occurred. We also assessed time in specified INR ranges per nursing home resident day on warfarin. RESULTS: Over the 12-month observation period, 720 adverse warfarin-related events and 253 potential adverse warfarin-related events were identified. Of the adverse warfarin-related events, 625 (87%) were characterized as minor, 82 (11%) were deemed serious, and 13 (2%) were life-threatening or fatal. Overall, 29% of the adverse warfarin-related events were judged to be preventable. Serious, life-threatening, or fatal events occurred at a rate of 2.49 per 100 resident-months; 57% of these more severe events were considered preventable. Errors resulting in preventable events occurred most often at the prescribing and monitoring stages of warfarin management. The percentages of time in the less than 2, 2 to 3, and more than 3 INR ranges were 36.5%, 49.6%, and 13.9%, respectively. CONCLUSIONS: The use of warfarin in the nursing home setting presents substantial safety concerns for patients. Adverse events associated with warfarin therapy are common and often preventable in the nursing home setting. Prevention strategies should target the prescribing and monitoring stages of warfarin management. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:539 / 544
页数:6
相关论文
共 30 条
[1]  
Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690
[2]   Effect of computerized physician order entry and a team intervention on prevention of serious medication errors [J].
Bates, DW ;
Leape, LL ;
Cullen, DJ ;
Laird, N ;
Petersen, LA ;
Teich, JM ;
Burdick, E ;
Hickey, M ;
Kleefield, S ;
Shea, B ;
Vander Vliet, M ;
Seger, DL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (15) :1311-1316
[3]   INCIDENCE OF ADVERSE DRUG EVENTS AND POTENTIAL ADVERSE DRUG EVENTS - IMPLICATIONS FOR PREVENTION [J].
BATES, DW ;
CULLEN, DJ ;
LAIRD, N ;
PETERSEN, LA ;
SMALL, SD ;
SERVI, D ;
LAFFEL, G ;
SWEITZER, BJ ;
SHEA, BF ;
HALLISEY, R ;
VANDERVLIET, M ;
NEMESKAL, R ;
LEAPE, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (01) :29-34
[4]   The costs of adverse drug events in hospitalized patients [J].
Bates, DW ;
Spell, N ;
Cullen, DJ ;
Burdick, E ;
Laird, N ;
Petersen, LA ;
Small, SD ;
Sweitzer, BJ ;
Leape, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (04) :307-311
[5]   Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation [J].
Fang, MC ;
Chang, YC ;
Hylek, EM ;
Rosand, J ;
Greenberg, SM ;
Go, AS ;
Singer, DE .
ANNALS OF INTERNAL MEDICINE, 2004, 141 (10) :745-752
[6]   Recent trends in disability and functioning among in the United States - A systematic review [J].
Freedman, VA ;
Martin, LG ;
Schoeni, RF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (24) :3137-3146
[7]   Ximelagatran - Promises and concerns [J].
Gurewich, V .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (06) :736-739
[8]   Atrial fibrillation and stroke prevention with warfarin in the long-term care setting [J].
Gurwitz, JH ;
Monette, J ;
Rochon, PA ;
Eckler, MA ;
Avorn, J .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (09) :978-984
[9]   Incidence and preventability of adverse drug events in nursing homes [J].
Gurwitz, JH ;
Field, TS ;
Avorn, J ;
McCormick, D ;
Jain, S ;
Eckler, M ;
Benser, M ;
Edmondson, AC ;
Bates, DW .
AMERICAN JOURNAL OF MEDICINE, 2000, 109 (02) :87-94
[10]   The incidence of adverse drug events in two large academic long-term care facilities [J].
Gurwitz, JH ;
Field, TS ;
Judge, J ;
Rochon, P ;
Harrold, LR ;
Cadoret, C ;
Lee, M ;
White, K ;
LaPrino, J ;
Erramuspe-Mainard, J ;
DeFlorio, M ;
Gavendo, L ;
Auger, J ;
Bates, DW .
AMERICAN JOURNAL OF MEDICINE, 2005, 118 (03) :251-258